Evidence & resources
Evidence for your study
Explore model characterization, efficacy, safety and immune-study evidence, then connect with suitable models, assays and study plans.
Find relevant cases, model characterization and technical resources by project goal, organ or content type.
Showing 9 of 26 resources
PDO 2.0 tumor–immune response
TRiCBIO PDO 2.0 studies in clear-cell renal cell carcinoma (ccRCC) and non-small-cell lung cancer (NSCLC) combine tissue identity, immune baseline and treatment-response readouts to guide immuno-oncology study design.
Explore the study data ↗
ADC distribution & response in breast PDOs
Two breast PDO studies pair antibody/nanobody distribution with ADC-associated morphology and viability to guide imaging, dose design and efficacy comparisons.
Explore the study data ↗ALI-PDO white paper: principles, applications & study design
Explore ALI-PDO principles and applications in studies of tissue architecture, immune context and drug response, with guidance on model choice, assay combinations and study design.
Explore and request the white paper ↗
Kidney organoids for safety and injury research
Explore kidney identity, molecular injury markers and morphology over time through cisplatin and doxorubicin studies.
Explore the case and results ↗
Human intestinal organoid IBD-like inflammation study
Human intestinal organoid study showing inflammatory morphology, FITC-Dextran, IL-8 and image-based candidate readouts.
View the resource ↗
Colorectal cancer PDO 2.0: tissue & immune profiling
Source-tissue and PDO histology are compared with CD3, CD20, Pan-CK and Ki67 readouts to establish tissue and immune context for the study.
Explore the case and results ↗
NSCLC PDO 2.0: immune baseline & IL-2 comparison
Compare CD4/CD8 tumor-infiltrating lymphocyte (TIL) counts across non-small-cell lung cancer (NSCLC) PDO 2.0 samples and IL-2 conditions to characterize immune baseline and inform subsequent assay design.
Explore the case and results ↗How an organoid project discussion begins
Begin with non-confidential context so the scientific team can understand the objective, identify suitable models and assays, and prepare a project outline.
See how projects start ↗
Normal lung organoids: identity and LPS injury
ATII and SCGB1A1/KRT5 profiling, serial morphology, and AT1/AT2 changes after LPS exposure together guide pulmonary-injury model selection, observation timing and endpoint design.
View model characterization ↗
Adjacent non-tumor liver organoids
Serial culture and H&E show tissue morphology; a CK19-positive, SMA-negative panel supports epithelial characterization.
View model characterization ↗
Mesenchymal tumor organoid development
GIST culture morphology and pathology plus osteosarcoma tissue and PDO markers show how two projects guide model QC and follow-on assays.
Explore the case and results ↗
PDOX: organoid-to-in vivo validation
Define when a PDO program should extend into PDOX and how model identity, in vivo growth, histology and efficacy are evaluated together.
Read the application note ↗
Breast cancer PDO: phenotype & tissue identity
Assess ER and Ki67 phenotypes alongside source-tissue/PDO histology to establish model identity and select efficacy endpoints.
Explore the case and results ↗
Renal cancer PDO 2.0: apoptosis & immune response
Source-tissue/PDO histology establishes model context; Annexin V/PI and CD3/CD8 flow compare apoptosis and immune change across treatment conditions.
Explore the case and results ↗
PDAC PDO 2.0: epithelial identity & immune readouts
Compare source-tissue and PDO histology with CK19/CD3 immunofluorescence and CD3/CD8/CD107a flow to assess epithelial identity and immune readouts.
Explore the case and results ↗PDO 1.0 vs PDO 2.0: choosing a culture system
Compare the biology each culture system can preserve and measure, then select or combine them around mechanism, endpoints and sample context.
See decision logic and use cases ↗
PUBLISHED GRAPHICAL ABSTRACTALI tumor–immune organoids | Platform & programs
Explore how ALI tumor–immune organoids can support sample profiling, immunotherapy candidate evaluation and functional assay design—and how TRiCBIO can support your program.
See program relevance and key figures ↗
Endometrial organoid profiling
Evaluate primary establishment and passage with H&E, E-cadherin and Ki67, plus ER, PR and FOXO1 profiling, to assess identity and stage-dependent change.
View model characterization ↗
Multi-organoid culture and tissue comparison
Culture, histology and passaging studies across organ systems show serial growth and morphological correspondence with source tissue.
Explore the case and results ↗Choosing among organoid, 2D and PDX models
Compare 2D, organoid and PDX models by biological context, timing and throughput to choose the system that best fits the program goal.
See decision logic and use cases ↗
HCC PDO and PDO 2.0: culture format and tissue identity
HCC PDO and PDO 2.0 studies combine culture morphology, source-tissue comparison, CD31 and the figure-labelled HEP-1 staining to guide efficacy and mechanism endpoints.
Explore the case and results ↗
Liver cancer PDO 2.0: morphology and tissue identity
Culture morphology, source-tissue/PDO H&E and hepatocyte- and endothelial-related IHC guide efficacy and mechanism endpoints in liver-cancer studies.
View model characterization ↗
Normal gastric organoids: culture & histology
P0–P2 culture, H&E, Ki67 and mucin-associated immunofluorescence show growth across passages and epithelial features.
View model characterization ↗
ADC distribution & efficacy in organoids
Plan ADC distribution imaging and efficacy readouts, with optional whole-organoid imaging or quantitative penetration analysis.
Read the application note ↗
Glioma PDO 2.0: tissue, lineage and functional profiling
Explore glioma PDO 2.0 through histology, lineage markers, CD31 and treatment-response studies.
Explore the case and results ↗
Normal lung and kidney evidence for safety studies
Plan a coordinated lung and kidney safety study using organ-specific injury evidence, identity QC and readouts tailored to one candidate program.
Read the application note ↗Continue with more case studies, research resources and project guides.
Match the model, assays and study to your objective
Tell us about the candidate, sample conditions and key research question. Our scientists will recommend the models, assays and study approach that best fit the project.